The development of bone marrow injection therapy for chronic myocardial ischemia

2003 Fiscal Year Final Research Report Summary

• Project/Area Number: 14370413
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Thoracic surgery
• Research Institution: Kyushu University
• Principal Investigator: HARADA Mine Kyushu University, Professor, 医学研究院, 教授 (00019621)
• Co-Investigator(Kenkyū-buntansha): MASUDA Munetaka Kyushu University, Assistant professor, 大学病院, 講師 (10190365) ; SHIMOKAWA Hiroaki Kyushu University, Associate professor, 医学研究院, 助教授 (00235681) ; MORITA Shigeki Kyushu University, Associate professor, 医学研究院, 助教授 (70243938) ; NISHIDA Takahiro Kyushu University, Instructor, 大学病院, 助手 (50284500) ; EGASHIRA Kensuke Kyushu University, Assistant professor, 大学病院, 講師 (60260379)
• Project Period (FY): 2002 – 2003
• Keywords: Bone marrow cell / Chronic myocardial ischemia

Research Abstract

Method and Results : A porcine model of chronic myocardial ischemia was made by placing an ameroid constrictor at the proximal segment of the left circumflex coronary artery, which resulted in sustained decrease in blood flow and myocardial contraction in vivo in 4 weeks. Thereafter, bone marrow cell injection therapy to the ischemic myocardial region was performed, which induced a complete recovery of wall thickening fraction and regional myocardial blood flow(RMBF) of the ischemic region in 4 weeks. By contrast, animals that did not receive the therapy had sustained myocardial dysfunction and RMBF. Neither arrhythmias nor other complications were observed during or after the bone marrow cell injection therapy. We observed the long term(over 1 year) safety after bone marrow cell injection therapy. Two patients who suffered from severe ischemic heart disease underwent the CD34 positive cell injection therapy. The outcome was excellent and we observed the reduced myocardial ischemia in those two patients.
Conclusions : These results suggest that bone marrow derived cell injection therapy is an effective and less-invasive therapeutic strategy for ischemic heart disease.